The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans

  • Antimicrob Agents Chemother. 2015 Feb;59(2):1341-3. doi: 10.1128/AAC.04228-14.
Nathan P Wiederhold  1 ,  Laura K Najvar  2 ,  Annette W Fothergill  3 ,  Rosie Bocanegra  2 ,  Marcos Olivo  2 ,  Dora I McCarthy  3 ,  William R Kirkpatrick  2 ,  Yoshiko Fukuda  4 ,  Junichi Mitsuyama  4 ,  Thomas F Patterson  2
Affiliations
  • 1. University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA [email protected].
  • 2. University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA South Texas Veterans Health Care System, San Antonio, Texas, USA.
  • 3. University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
  • 4. Toyama Chemical Co., Ltd., Toyama, Japan.
PMID: 25451054 DOI: 10.1128/AAC.04228-14
Abstract

We evaluated the in vitro and in vivo activities of the investigational arylamidine T-2307 against echinocandin-resistant Candida albicans. T-2307 demonstrated potent in vitro activity, and daily subcutaneous doses between 0.75 and 6 mg/kg of body weight significantly improved survival and reduced Fungal burden compared to placebo control and caspofungin (10 mg/kg/day) in mice with invasive candidiasis caused by an echinocandin-resistant strain. Thus, T-2307 may have potential use in the treatment of echinocandin-resistant C. albicans infections.

Products